西那卡塞对维持性血液透析继发甲状旁腺功能亢进患者血清FGF-23的影响被引量：13

Effect of cinacalcet on serum fibroblast growth factor-23 in maintenance hemodialysis patients with secondary hyperparathyroidism

原文传递

导出

摘要目的探讨西那卡塞(cinacalcet)对维持性血液透析继发性甲状旁腺功能亢进症(SHPT)患者血清成纤维细胞生长因子23(FGF-23)表达的影响和意义。方法维持性血液透析SHPT患者32例服用西那卡塞,观察患者治疗前及治疗1、3个月时的血清FGF-23、血钙、血磷和血清全段甲状旁腺激素(iPTH)等指标变化。结果治疗3个月时的血清FGF-23低于治疗前和治疗1个月[(751.50±90.97)ng/L vs.(849.60±81.94)ng/L和(826.90±79.40)ng/L](P<0.01)。治疗1、3个月时的血磷为(1.89±0.56)mmol/L和(1.75±0.39)mmol/L,低于治疗前的(2.48±0.66)mmol/L(P<0.05);治疗1、3个月时的血清iPTH为(1014.0±667.7)pg/ml和(838.0±680.9)pg/ml,低于治疗前的(1535±561.10)pg/ml(P<0.05)。结论西那卡塞可明显降低维持性血液透析SHPT患者血清FGF-23、iPTH和血磷水平。 Objective To investigate the influences and significance of cinacalcet on serum fibroblast growth factor-23（FGF-23） expression in maintenance hemodialysis patients with secondary hyperparathyroidism（SHPT）. Methods Thirty-two maintenance hemodialysis SHPT patients were treated with cinacalcet for 3 months. Serum levels of FGF-23, calcium, phosphorus and entire parathyroid hormone（iP＇FH） were measured before and during treatment for 1 and 3 months. Results Serum FGF-23 level in the 3rd month was lower than that before and in the Ist month[（751.50± 90. 97） ng/L vs. （849.60 ± 81.94） ng/L and （826.90± 79.40） ng/L] （P〈0. 01）. Serum level of phosphorus was lower in the 1st and and month during treatment than that before [（1.89± 0. 56） mmol/L and （1.75± 01. 39） mmol/L vs. （2.48±0.66） mmol/L] （P〈0. 05）. So did serum level of iPTH [（1014. 0±667. 7） pg/ml and （838.0±680. 9） pg/ml vs. （1535±561.10） pg/ml] （P〈0. 05）. Conclusion Cinacalcet can significantly reduce serum levels of FGF-23, iPTH and phosphorus in SHPT patients underg,oing maintenance hemodialysis.

作者缪立英金丽娜沈建琴朱滨

机构地区苏州大学附属第三医院(常州市第一人民医院)血液净化中心苏州大学附属第三医院(常州市第一人民医院)重症医学科

出处《江苏医药》 CAS 2016年第13期1447-1449,共3页 Jiangsu Medical Journal

关键词维持性血液透析成纤维细胞生长因子23 西那卡塞继发性甲状旁腺功能亢进症 Maintenance hemodialysis Fibroblast growth factor-23 Cinacalcet Secondary hyperparathyroidism

分类号 R582 [医药卫生—内分泌]

引文网络
相关文献

参考文献11

1Cunningham J,Locatelli F,Rodriguez M,et al.Secondary hyperparathyroidism:pathogenesis,disease progression,and therapeutic options[J].Clin J Am Soc Nephrol,2011,6(4):913-921.
2Ballinger AE,Palmer SC,Nistor I,et al.Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients[J].Cochrane Database Syst Rev,2014(12):CD006254.
3Bergwitz C,Jüppner H.Regulation of phosphate homeostasis by PTH,vitamin D,and FGF23[J].Annu Rev Med,2010,61:91-104.
4Damasiewicz MJ,Toussaint ND,Polkinghorne KR.Fibroblast growth factor 23in chronic kidney disease:new insights and clinical implications[J].Nephrology(Carlton),2011,16(3):261-268.
5Komaba H,Goto S,Fujii H,et al.Depressed expression of Klotho and FGF receptor 1in hyperplastic parathyroid glands from uremic patients[J].Kidney Int,2010,77(3):232-238.
6Hu P,Xuan Q,Hu B,et al.Fibroblast growth factor-23helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease[J].Int J Biol Sci,2012,8(5):663-671.
7Zhang Q,Li M,You L,et al.Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism:a meta-analysis[J].PLoS One,2012,7(10):e48070.
8Kuczera P,Adamczak M,Wiecek A.Cinacalcet treatment decreases plasma fibroblast growth factor 23concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism[J].Clin Endocrinol(Oxf),2014,80(4):607-612.
9Wetmore JB,Liu S,Krebill R,et al.Effects of cinacalcet and concurrent low-dose vitamin D on FGF23levels in ESRD[J].Clin J Am Soc Nephrol,2010,5(1):110-116.
10Hryszko T,Brzosko S,Rydzewska-Rosolowska A,et al.Cinacalcet lowers FGF-23level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism[J].Int Urol Nephrol,2012,44(5):1479-1486.